101. Sirolimus-induced Hypertriglyceridemia Leads to Acute Pancreatitis and Diabetic Ketoacidosis Post Stem Cell Transplant for Sickle Cell Disease.
- Author
-
Paul S, Nirmal G, Chadha V, Sharma R, Kochar I, Jerath N, Vohra R, and Kharya G
- Subjects
- Humans, Sirolimus therapeutic use, Acute Disease, Immunosuppressive Agents adverse effects, Stem Cell Transplantation adverse effects, Diabetic Ketoacidosis chemically induced, Diabetic Ketoacidosis therapy, Diabetic Ketoacidosis complications, Pancreatitis chemically induced, Pancreatitis therapy, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects, Hypertriglyceridemia chemically induced, Hypertriglyceridemia therapy, Hypertriglyceridemia complications, Anemia, Sickle Cell therapy, Anemia, Sickle Cell drug therapy, Diabetes Mellitus chemically induced, Diabetes Mellitus drug therapy
- Abstract
Sirolimus (mammalian target of rapamycin inhibitor) is a potent immunosuppressive agent, used in patients receiving hematopoietic stem cell transplant (HSCT) for Graft vs Host disease prophylaxis. Compared to calcineurin inhibitors, sirolimus has no neurotoxicity or nephrotoxicity, but sirolimus causes dose-dependent thrombocytopenia, leukopenia, delayed wound healing, hyperlipidemia, and hypertriglyceridemia. Here we report a case of acute pancreatitis and diabetic ketoacidosis in a patient with sickle cell disease post haploidentical family donor HSCT which was managed conservatively without plasmapheresis. Based on our review of the literature, this is the first reported case of developing acute pancreatitis as an adverse effect of sirolimus-induced hypertriglyceridemia leading to diabetic ketoacidosis in a recipient of HSCT., Competing Interests: The authors declare no conflict of interest., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF